CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab
- 357 Downloads
Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a human CD20-specific chimeric antibody extensively used in B-NHL therapy. We investigated whether conjugation to calicheamicin can improve the anti-tumor activity of rituximab against human B-cell lymphoma (BCL) xenografts in preclinical models. BCL cells were cultured with rituximab or its calicheamicin conjugates and their in vitro growth was monitored. BCL cells were injected s.c. to establish localized xenografts in nude mice or i.v. to establish disseminated BCL in severe combined immunodeficient (scid) mice. I.p. treatment with rituximab or its calicheamicin conjugates was initiated and its effect on s.c. BCL growth or survival of mice with disseminated BCL was monitored. Conjugation of calicheamicin to rituximab vastly enhanced its growth inhibitory activity against BCL in vitro. Conjugation to calicheamicin had no deleterious effect on the effector functional activity of rituximab. Calicheamicin conjugated to rituximab with an acid-labile linker exhibited greater anti-tumor activity against s.c. BCL xenografts and improved survival of mice with disseminated BCL over that of unconjugated rituximab. Anti-tumor activities of rituximab conjugated to calicheamicin via an acid-stable linker were similar to that of unconjugated rituximab. Superior anti-tumor efficacy exhibited by a calicheamicin immunoconjugate of rituximab with an acid-labile linker over that of rituximab demonstrates the therapeutic potential of CD20-specific antibody-targeted chemotherapy strategy in the treatment of B-NHL.
KeywordsCalicheamicin Rituximab CD20 Immunoconjugates Anti-tumor
N-Acetyl gamma calicheamicin dimethyl derivative(s)
We thank Fred Immermann of Wyeth Biometrics Research for statistical analysis of the data.
- 16.Advani A, Giné E, Gisselbrecht C et al (2005) Preliminary report of a phase 1 study of cmc-544, an antibody-targeted chemotherapy agent, in patients with b-cell non-Hodgkin’s lymphoma (NHL). Blood 106(11): abstract No. 230Google Scholar
- 20.Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU (1995) Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used alone in combination than with either immunotoxin alone. Int J Cancer 62:337–344PubMedCrossRefGoogle Scholar
- 21.Hinman LM, Hamann PR, Wallace R, Menendez AT, Dur FE, Upeslacis J (2003) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53:3336–3342Google Scholar
- 28.Van Den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, Van De Winkel JG (1994) Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol 152:574–585Google Scholar
- 33.Harder T, Engelhardt (2004) Membrane domains in lymphocytes-from lipid rafts to protein scaffolds. Traffic 5:265–275Google Scholar